Communicable Diseases: Clinical Trials

1,558 trials for Communicable Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1204 completed, 112 unknown, 101 terminated, 47 withdrawn. 1558 Phase 3, 160 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 31558Completed 1204, Unknown 112, Terminated 101, Withdrawn 47, Active not recruiting 44, Recruiting 28, Not yet recruiting 20, Suspended 2
Phase 2160Completed 102, Terminated 19, Unknown 15, Withdrawn 11, Recruiting 5, Active not recruiting 4, Not yet recruiting 3, Suspended 1

Follow Communicable Diseases: new trials by email Literature Review of Communicable Diseases trials Research Report on Communicable Diseases

Trials (filtered) newest first · largest first

All 1,558 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD)
Phase 2 / Phase 3Not yet recruitingMassachusetts General Hospital1242027-03-012026-10-23
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Zopapogene imadenovec-drba - Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis
Phase 3Not yet recruitingPrecigen, Inc152026-12-312026-10-28
A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
Doxycycline hyclate, Standard of Care for STI prevention - Sexually Transmitted Infection (STI), Gonorrhea
Phase 3Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)5802026-11-302026-10-20
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection
Phase 3Not yet recruitingUniversity College, London8002026-11-012026-08-28
Naproxen Versus Placebo as Adjunct Treatment of Cellulitis
enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious
Phase 3Not yet recruitingOttawa Hospital Research Institute8842026-11-012026-10-20
Study of BK1803 in Healthy Infants
BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria
Phase 3RecruitingTanabe Pharma Corporation3442026-10-212026-11-12
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)
V503, Placebo - Papillomavirus Infections
Phase 3RecruitingMerck Sharp & Dohme LLC9302026-10-102026-10-22
Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
Intralesional Acyclovir, Intralesional Zinc Sulphate - Warts, Plantar Warts
Phase 3Not yet recruitingAssiut University762026-10-012026-09-29
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster - Human Papillomavirus (HPV) Infection
Phase 3Not yet recruitingPT Bio Farma2662026-10-012026-09-17
Study Interchangeability Hep-B Vaccine Administered at Birth Dose
In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine
Phase 3Not yet recruitingPT Bio Farma2702026-10-012026-10-02
Treatment of CKD Patients With HCV
SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients
Phase 2 / Phase 3Not yet recruitingTanta University502026-09-152026-08-20
Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections
Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml), Rectal swab for ESBL-E and microbiota (Eswab), Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) - Neisseria Gonorrhoeae (Ng) Infections
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris3602026-09-012026-06-22
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
Pegylated liposomal doxorubicin, Paclitaxel - Kaposi Sarcoma, HIV-1-infection
Phase 3Not yet recruitingAIDS Malignancy Consortium1302026-09-012026-01-23
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B
Phase 3Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.9302026-09-012026-10-02
Early Corticosteroids in Severe Influenza Pneumonia
Dexametasone, Sodium chloride 0.9% (placebo) - Severe Influenza, Intensive Care (ICU)
Phase 3Not yet recruitingCentre Hospitalier Régional Metz-Thionville5442026-09-012026-08-28
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection
Phase 3Not yet recruitingHIV Prevention Trials Network4002026-09-012026-06-22
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) - HIV Infections
Phase 3RecruitingViiV Healthcare1972026-07-212026-11-13
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections
Phase 3RecruitingGilead Sciences5902026-07-142026-08-14
500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection
ceftriaxone 500-mg, ceftriaxone 1000-mg - Gonorrhea Infection
Phase 3RecruitingNational Taiwan University Hospital4002026-07-012026-07-17
Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B
GST-HG141 - Chronic Hepatitis b
Phase 3Not yet recruitingFujian Akeylink Biotechnology Co., Ltd.5762026-06-262026-05-14

Showing 20 of 1558. Sign in to see all of them.

Narrower conditions

HIV Infections (600)  ·  Hepatitis C (284)  ·  Acquired Immunodeficiency Syndrome (269)  ·  Hepatitis C, Chronic (201)  ·  Hepatitis B (195)  ·  Papillomavirus Infections (101)  ·  Hepatitis B, Chronic (85)  ·  Tetanus (58)  ·  Diphtheria (57)  ·  Whooping Cough (48)  ·  Haemophilus Infections (47)  ·  Infections (46)  ·  Sexually Transmitted Diseases (45)  ·  Uterine Cervical Neoplasms (45)

Broader conditions

Infections (1512)  ·  Virus Diseases (1447)  ·  Blood-Borne Infections (1333)  ·  RNA Virus Infections (1139)  ·  Urogenital Diseases (901)  ·  Genital Diseases (892)  ·  Sexually Transmitted Diseases (847)  ·  Sexually Transmitted Diseases, Viral (847)  ·  Immune System Diseases (728)  ·  Lentivirus Infections (718)  ·  Retroviridae Infections (718)  ·  Immunologic Deficiency Syndromes (717)  ·  Digestive System Diseases (662)  ·  Hepatitis, Viral, Human (641)

Interventions

Ribavirin (202)  ·  peginterferon alfa-2a (101)  ·  Lamivudine (84)  ·  Ritonavir (76)  ·  Tenofovir (76)  ·  Zidovudine (67)  ·  efavirenz (62)  ·  peginterferon alfa-2b (61)  ·  Sofosbuvir (49)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (48)  ·  Lopinavir (39)  ·  Nevirapine (36)  ·  Raltegravir Potassium (32)  ·  abacavir (32)  ·  daclatasvir (32)

Sponsors

Merck Sharp & Dohme LLC (120)  ·  GlaxoSmithKline (114)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (109)  ·  Gilead Sciences (76)  ·  Bristol-Myers Squibb (60)  ·  ViiV Healthcare (51)  ·  AbbVie (48)  ·  French National Agency for Research on AIDS and Viral Hepatitis (35)  ·  Hoffmann-La Roche (30)  ·  Boehringer Ingelheim (24)  ·  Sanofi Pasteur, a Sanofi Company (23)  ·  ANRS, Emerging Infectious Diseases (19)  ·  Glaxo Wellcome (17)  ·  Centers for Disease Control and Prevention (11)  ·  Harvard School of Public Health (HSPH) (11)

Countries

United States (590)  ·  Canada (233)  ·  France (217)  ·  Spain (196)  ·  Germany (173)  ·  Puerto Rico (167)  ·  United Kingdom (167)  ·  Italy (150)  ·  Australia (134)  ·  Belgium (123)  ·  South Africa (118)  ·  Thailand (106)  ·  China (96)  ·  Russia (90)  ·  Brazil (85)

Top investigators

Connie Celum, MD, MPH (5)  ·  Feinberg J (5)

Results publications

PMID 41276263, PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 27422279, PMID 29377566, PMID 29404492, PMID 19935017, PMID 28193518, PMID 32184277, PMID 39324693, PMID 25040192, PMID 25583164, PMID 26743093, PMID 27847279, PMID 30868245, PMID 33901188, PMID 35174470, PMID 18657709, PMID 19236277, PMID 19236279, PMID 19571722, PMID 24979445, PMID 25424785, PMID 25445400, PMID 25992639, PMID 26947564, PMID 27553375, PMID 29074187, PMID 29211620, PMID 29767684, PMID 30982556, PMID 31824976, PMID 32829410, PMID 35149535, PMID 35508986, PMID 36740893, PMID 37452174, PMID 38160309, PMID 39052748, PMID 39101506, PMID 41166720, PMID 16890833, PMID 17716936, PMID 18532873, PMID 18832244, PMID 18832245

NIH funding

2014 (33), 2015 (29), 2009 (15), 2016 (13), 2004 (11), 2008 (10), 2017 (10), 2005 (8), 2019 (7), 2025 (4), U01CA121947 (4), 2023 (3), U01AI068636 (3), U01DK082843 (3), U01DK082864 (3)